News Home

What is the Market's View on Neurosense Therapeutics Ltd (NRSN) Stock's Price and Volume Trends Wednesday?

Wednesday, February 28, 2024 01:33 PM | InvestorsObserver Analysts

Mentioned in this article

What is the Market's View on Neurosense Therapeutics Ltd (NRSN) Stock's Price and Volume Trends Wednesday?

The market has been high on Neurosense Therapeutics Ltd (NRSN) stock recently. NRSN gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bullish
Neurosense Therapeutics Ltd has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on NRSN!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With NRSN Stock Today?

Neurosense Therapeutics Ltd (NRSN) stock is up 1.67% while the S&P 500 is down -0.05% as of 1:31 PM on Wednesday, Feb 28. NRSN is higher by $0.03 from the previous closing price of $1.80 on volume of 403,543 shares. Over the past year the S&P 500 has risen 27.45% while NRSN is down -4.69%. NRSN lost -$0.86 per share in the over the last 12 months.

More About Neurosense Therapeutics Ltd

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its lead product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio. Click Here to get the full Stock Report for Neurosense Therapeutics Ltd stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App